136 related articles for article (PubMed ID: 25561982)
1. The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data.
Jang HJ; Cho JW; Park B; Choi HC; Kim HS; Kim JH
J Cancer; 2015; 6(2):169-76. PubMed ID: 25561982
[TBL] [Abstract][Full Text] [Related]
2. Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer.
Kim HS; Kim JH; Yang I
Lung Cancer; 2014 Sep; 85(3):385-9. PubMed ID: 25074845
[TBL] [Abstract][Full Text] [Related]
3. Ideal number of target lesions per organ to measure in metastatic colorectal cancer.
Kim HS; Kim JH
Oncol Lett; 2014 Oct; 8(4):1896-1900. PubMed ID: 25202433
[TBL] [Abstract][Full Text] [Related]
4. Single-lesion measurement per organ for assessing tumor response in advanced gastric cancer.
Kim HS; Kim JW; Kim JH; Choi DR; Han AR; Kim MJ; Kim BC; Zang DY
Oncology; 2015; 88(2):69-75. PubMed ID: 25277674
[TBL] [Abstract][Full Text] [Related]
5. Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer.
Jung SG; Kim JH; Kim HS; Kim KJ; Yang I
Chin J Cancer Res; 2016 Apr; 28(2):161-7. PubMed ID: 27199513
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy.
Choi HC; Kim JH; Kim HS; Jung SG; Hwang SM; Ju SB; Yang I
J Cancer; 2015; 6(7):652-7. PubMed ID: 26078796
[TBL] [Abstract][Full Text] [Related]
7. Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis.
Kim JH; Min SJ; Jang HJ; Cho JW; Kim SH; Kim HS
J Cancer; 2015; 6(4):387-93. PubMed ID: 25767610
[TBL] [Abstract][Full Text] [Related]
8. Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor.
He LN; Chen T; Fu S; Jiang Y; Zhang X; Chen C; Du W; Luo L; Li A; Wang Y; Yu H; Zhou Y; Wang Y; Yang Y; Huang Y; Zhao H; Fang W; Zhang L; Hong S
Ther Adv Med Oncol; 2023; 15():17588359231200463. PubMed ID: 37881238
[TBL] [Abstract][Full Text] [Related]
9. Comparison of RECIST 1.0 and RECIST 1.1 on computed tomography in patients with metastatic colorectal cancer.
Jang HJ; Kim BC; Kim HS; Kim JH; Song HH; Kim JB; Park JJ; Yoon SN; Woo JY; Zang DY
Oncology; 2014; 86(2):117-21. PubMed ID: 24480800
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review.
Kim JH
Oncotarget; 2016 Mar; 7(12):13680-7. PubMed ID: 26885610
[TBL] [Abstract][Full Text] [Related]
11. CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure.
Zacharia TT; Saini S; Halpern EF; Sumner JE
AJR Am J Roentgenol; 2006 Apr; 186(4):1067-70. PubMed ID: 16554580
[TBL] [Abstract][Full Text] [Related]
12. Individual patient data analysis to assess modifications to the RECIST criteria.
Bogaerts J; Ford R; Sargent D; Schwartz LH; Rubinstein L; Lacombe D; Eisenhauer E; Verweij J; Therasse P;
Eur J Cancer; 2009 Jan; 45(2):248-60. PubMed ID: 19095437
[TBL] [Abstract][Full Text] [Related]
13. Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor.
Egger ME; Cannon RM; Metzger TL; Nowacki M; Kelly L; Tatum C; Scoggins CR; Callender GG; McMasters KM; Martin RC
J Am Coll Surg; 2013 Apr; 216(4):845-56; discussion 856-7. PubMed ID: 23415549
[TBL] [Abstract][Full Text] [Related]
14. Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy.
He LN; Chen T; Fu S; Chen C; Jiang Y; Zhang X; Du W; Li H; Wang Y; Ali WAS; Zhou Y; Lin Z; Yang Y; Huang Y; Zhao H; Fang W; Zhang L; Hong S
Lung Cancer; 2022 Mar; 165():10-17. PubMed ID: 35051754
[TBL] [Abstract][Full Text] [Related]
15. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
16. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.
Kim JH; Kim BJ; Jang HJ; Kim HS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):729-735. PubMed ID: 28780726
[TBL] [Abstract][Full Text] [Related]
18. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review.
Min SJ; Jang HJ; Kim JH
Oncotarget; 2016 May; 7(19):27848-54. PubMed ID: 27036043
[TBL] [Abstract][Full Text] [Related]
20. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
Mazumdar M; Smith A; Schwartz LH
J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
